{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:20:23Z","timestamp":1788344423457,"version":"build-2803163510"},"reference-count":162,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["22377084"],"award-info":[{"award-number":["22377084"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Support Program of Science & Technology Department of Sichuan Provincial","award":["2025ZNSFSC0691"],"award-info":[{"award-number":["2025ZNSFSC0691"]}]},{"name":"the Open Project of Individualized Drug Therapy Key Laboratory of Sichuan Province","award":["2024YB01"],"award-info":[{"award-number":["2024YB01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Chem Res"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00044-026-03605-7","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T05:26:26Z","timestamp":1786944386000},"page":"1626-1666","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual-target carbonic anhydrase inhibitors in cancer therapy: progress, challenges, and opportunities"],"prefix":"10.1007","volume":"35","author":[{"given":"Meizhen","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinmei","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin-Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifa","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianhai","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"3605_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.bioorg.2025.108224","volume":"156","author":"P Singh","year":"2025","unstructured":"Singh P, Arifuddin M, Supuran C, Nerella S. Carbonic anhydrase inhibitors: Structural insights and therapeutic potential. Bioorg Chem. 2025;156:16. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108224.","journal-title":"Bioorg Chem"},{"key":"3605_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.bmc.2021.116140","volume":"39","author":"E Buabeng","year":"2021","unstructured":"Buabeng E, Henary M. Developments of small molecules as inhibitors for carbonic anhydrase isoforms. Bioorg Med Chem. 2021;39:23. https:\/\/doi.org\/10.1016\/j.bmc.2021.116140.","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"3605_CR3","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1080\/14756366.2021.1972995","volume":"36","author":"A Nocentini","year":"2021","unstructured":"Nocentini A, Supuran C, Capasso C. An overview on the recently discovered iota-carbonic anhydrases. J Enzym Inhib Med Chem. 2021;36(1):1988\u201395. https:\/\/doi.org\/10.1080\/14756366.2021.1972995.","journal-title":"J Enzym Inhib Med Chem"},{"issue":"1","key":"3605_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41467-020-18425-5","volume":"11","author":"J Kim","year":"2020","unstructured":"Kim J, Lee C, Lim S, Adhikari A, Andring J, McKenna R, et al. Elucidating the role of metal ions in carbonic anhydrase catalysis. Nat Commun. 2020;11(1):10. https:\/\/doi.org\/10.1038\/s41467-020-18425-5.","journal-title":"Nat Commun"},{"key":"3605_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.enzmictec.2025.110657","volume":"189","author":"A Allam","year":"2025","unstructured":"Allam A, Rudayni H, Ahmed N, Alkhayl F, Lamsabhi A, Kamel E. Comprehensive insights into carbonic anhydrase inhibition: A triad of In vitro, In silico, and In vivo perspectives. Enzyme Microb Technol. 2025;189:22. https:\/\/doi.org\/10.1016\/j.enzmictec.2025.110657.","journal-title":"Enzyme Microb Technol"},{"key":"3605_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejps.2025.107233","volume":"213","author":"J Kim","year":"2025","unstructured":"Kim J, Lee E, Vullo D, Mishra C, Supuran C, Jeon R. Design and Synthesis of Potent and Selective Urea-linked Benzenesulfonamide Analogs as Carbonic Anhydrase II Inhibitors. Eur J Pharm Sci. 2025;213:11. https:\/\/doi.org\/10.1016\/j.ejps.2025.107233.","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"3605_CR7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3109\/14756366.2012.737323","volume":"28","author":"M Aggarwal","year":"2013","unstructured":"Aggarwal M, Boone C, Kondeti B, McKenna R. Structural annotation of human carbonic anhydrases. J Enzym Inhib Med Chem. 2013;28(2):267\u201377. https:\/\/doi.org\/10.3109\/14756366.2012.737323.","journal-title":"J Enzym Inhib Med Chem"},{"issue":"14","key":"3605_CR8","doi-asserted-by":"publisher","first-page":"5444","DOI":"10.1021\/bi0475471","volume":"44","author":"S Gould","year":"2005","unstructured":"Gould S, Tawfik D. Directed evolution of the promiscuous esterase activity of carbonic anhydrase II. Biochemistry. 2005;44(14):5444\u201352. https:\/\/doi.org\/10.1021\/bi0475471.","journal-title":"Biochemistry"},{"key":"3605_CR9","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.ijbiomac.2016.10.073","volume":"95","author":"M Wahiduzzaman, Dar","year":"2017","unstructured":"Wahiduzzaman, Dar M, Hague M, Idrees D, Hassan M, Islam A, et al. Characterization of folding intermediates during urea-induced denaturation of human carbonic anhydrase II. Int J Biol Macromol. 2017;95:881\u20137. https:\/\/doi.org\/10.1016\/j.ijbiomac.2016.10.073.","journal-title":"Int J Biol Macromol"},{"issue":"7","key":"3605_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/ijms17071150","volume":"17","author":"C Lomelino","year":"2016","unstructured":"Lomelino C, Supuran C, McKenna R. Non-Classical Inhibition of Carbonic Anhydrase. Int J Mol Sci. 2016;17(7):13. https:\/\/doi.org\/10.3390\/ijms17071150.","journal-title":"Int J Mol Sci"},{"key":"3605_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ejmech.2025.117619","volume":"291","author":"W Fadaly","year":"2025","unstructured":"Fadaly W, Nemr M, Abd El-Hameed A, Giovannuzzi S, Alkabbani M, Hefina M, et al. Novel benzenesulfonamide derivatives linked to diaryl pyrazole tail as potential carbonic anhydrase II\/VII inhibitors with anti-epileptic activity. Eur J Med Chem. 2025;291:16. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117619.","journal-title":"Eur J Med Chem"},{"key":"3605_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.bioorg.2024.107881","volume":"153","author":"W Fadaly","year":"2024","unstructured":"Fadaly W, Mohamed F, Nemr M, Sayed A, Khalil R, Zidan T. Novel benzenesulfonamide derivatives as potential selective carbonic anhydrase IX, XII inhibitors with anti-proliferative activity: Design, synthesis and in silico studies. Bioorg Chem. 2024;153:16. https:\/\/doi.org\/10.1016\/j.bioorg.2024.107881.","journal-title":"Bioorg Chem"},{"issue":"42","key":"3605_CR13","doi-asserted-by":"publisher","first-page":"26241","DOI":"10.1039\/d1ra05277b","volume":"11","author":"M Nemr","year":"2021","unstructured":"Nemr M, AboulMagd A, Hassan H, Hamed A, Hamed M, Elsaadi M. Design, synthesis and mechanistic study of new benzenesulfonamide derivatives as anticancer and antimicrobial agents via carbonic anhydrase IX inhibition. RSC Adv. 2021;11(42):26241\u201357. https:\/\/doi.org\/10.1039\/d1ra05277b.","journal-title":"RSC Adv"},{"issue":"10","key":"3605_CR14","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1021\/acsmedchemlett.5c00443","volume":"16","author":"C Supuran","year":"2025","unstructured":"Supuran C. Human Carbonic Anhydrase Inhibitors. ACS Med Chem Lett. 2025;16(10):1889\u201395. https:\/\/doi.org\/10.1021\/acsmedchemlett.5c00443.","journal-title":"ACS Med Chem Lett"},{"key":"3605_CR15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/eye.1995.22","volume":"9","author":"I WIDENGARD","year":"1995","unstructured":"WIDENGARD I, MANDAHL A, TORNQUIST P, COLOR-VISION AND WISTRANDP, SIDE-EFFECTS DURING. TREATMENT WITH METHAZOLAMIDE. Eye. 1995;9:130\u20135. https:\/\/doi.org\/10.1038\/eye.1995.22.","journal-title":"Eye"},{"issue":"9","key":"3605_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ardp.70090","volume":"358","author":"M Ahmed","year":"2025","unstructured":"Ahmed M, Mehdi M, Javed M, AL Mughram M, Irfan M, Saeed A, et al. Structural Advances in Non-Sulfonamide Carbonic Anhydrase Inhibitors: Insights Into Design, Bioactivity, and Binding Mechanism. Arch Pharm. 2025;358(9):69. https:\/\/doi.org\/10.1002\/ardp.70090.","journal-title":"Arch Pharm"},{"issue":"9","key":"3605_CR17","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.tips.2025.07.002","volume":"46","author":"S Giovannuzzi","year":"2025","unstructured":"Giovannuzzi S, Supuran C. Human carbonic anhydrase modulators: the past, present, and future. Trends Pharmacol Sci. 2025;46(9):836\u201347. https:\/\/doi.org\/10.1016\/j.tips.2025.07.002.","journal-title":"Trends Pharmacol Sci"},{"issue":"7","key":"3605_CR18","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.tips.2024.05.005","volume":"45","author":"B Turgutalp","year":"2024","unstructured":"Turgutalp B, Kizil C. Multi-target drugs for Alzheimer\u2019s disease. Trends Pharmacol Sci. 2024;45(7):628\u201338. https:\/\/doi.org\/10.1016\/j.tips.2024.05.005.","journal-title":"Trends Pharmacol Sci"},{"key":"3605_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejmech.2024.116170","volume":"267","author":"S Liao","year":"2024","unstructured":"Liao S, Wu G, Xie Z, Lei X, Yang X, Huang S, et al. pH regulators and their inhibitors in tumor microenvironment. Eur J Med Chem. 2024;267:32. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116170.","journal-title":"Eur J Med Chem"},{"issue":"3","key":"3605_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1001\/jamaophthalmol.2021.5977","volume":"140","author":"M Popovic","year":"2022","unstructured":"Popovic M, Schlenker M, Thiruchelvam D, Redelmeier D. Serious Adverse Events of Oral and Topical Carbonic Anhydrase Inhibitors. JAMA Ophthalmol. 2022;140(3):235\u201342. https:\/\/doi.org\/10.1001\/jamaophthalmol.2021.5977.","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"3605_CR21","doi-asserted-by":"publisher","first-page":"5686","DOI":"10.1080\/07391102.2024.2310777","volume":"43","author":"N Bavandpour","year":"2025","unstructured":"Bavandpour N, Mehrabi M, Adibi H, Mehrabi M, Khodarahmi R. Synthesis of 4-sulfamoyl phenyl diazocarboxylic acid derivatives as novel non-classical inhibitors of human carbonic anhydrase II activity: an in vitro study. J Biomol Struct Dyn. 2025;43(12):5686\u2013700. https:\/\/doi.org\/10.1080\/07391102.2024.2310777.","journal-title":"J Biomol Struct Dyn"},{"key":"3605_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bmcl.2023.129411","volume":"93","author":"C Supuran","year":"2023","unstructured":"Supuran C. A simple yet multifaceted 90 years old, evergreen enzyme: Carbonic anhydrase, its inhibition and activation. Bioorg Med Chem Lett. 2023;93:26. https:\/\/doi.org\/10.1016\/j.bmcl.2023.129411.","journal-title":"Bioorg Med Chem Lett"},{"key":"3605_CR23","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1042\/bcj20160115","volume":"473","author":"C Supuran","year":"2016","unstructured":"Supuran C. Structure and function of carbonic anhydrases. Biochem J. 2016;473:2023\u201332. https:\/\/doi.org\/10.1042\/bcj20160115.","journal-title":"Biochem J"},{"key":"3605_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.abb.2025.110515","volume":"771","author":"C Efeoglu","year":"2025","unstructured":"Efeoglu C, Demir Y, T\u00fcrkes C, Yabalak E, Seferoglu Z, Nural Y. New 1,2,3-triazole derivatives as acetylcholinesterase and carbonic anhydrase inhibitors: Synthesis, molecular docking, and solubility. Arch Biochem Biophys. 2025;771:12. https:\/\/doi.org\/10.1016\/j.abb.2025.110515.","journal-title":"Arch Biochem Biophys"},{"issue":"5","key":"3605_CR25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/molecules23051045","volume":"23","author":"S Singh","year":"2018","unstructured":"Singh S, Lomelino C, Mboge M, Frost S, McKenna R. Cancer Drug Development of Carbonic Anhydrase Inhibitors beyond the Active Site. Molecules. 2018;23(5):22. https:\/\/doi.org\/10.3390\/molecules23051045.","journal-title":"Molecules"},{"issue":"1","key":"3605_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/ardp.202400776","volume":"358","author":"R Paciotti","year":"2025","unstructured":"Paciotti R, Carradori S, Angeli A, D\u2019Agostino I, Ferraroni M, Coletti C, et al. Unprecedented carbonic anhydrase inhibition mechanism: Targeting histidine 64 side chain through a halogen bond. Arch Pharm. 2025;358(1):10. https:\/\/doi.org\/10.1002\/ardp.202400776.","journal-title":"Arch Pharm"},{"issue":"11","key":"3605_CR27","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.1021\/ja01167a012","volume":"72","author":"WH Miller","year":"1950","unstructured":"Miller WH, Dessert AM, Roblin RO Jr. Heterocyclic Sulfonamides as Carbonic Anhydrase Inhibitors1. J Am Chem Soc. 1950;72(11):4893\u20136. https:\/\/doi.org\/10.1021\/ja01167a012.","journal-title":"J Am Chem Soc"},{"issue":"1\u20132","key":"3605_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0378-5173(02)00438-6","volume":"248","author":"I Kaur","year":"2002","unstructured":"Kaur I, Smitha R, Aggarwal D, Kapil M. Acetazolamide: future perspective in topical glaucoma therapeutics. Int J Pharm. 2002;248(1\u20132):1\u201314. https:\/\/doi.org\/10.1016\/s0378-5173(02)00438-6.","journal-title":"Int J Pharm"},{"key":"3605_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejmech.2020.112923","volume":"209","author":"S Kumar","year":"2021","unstructured":"Kumar S, Rulhania S, Jaswal S, Monga V. Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors. Eur J Med Chem. 2021;209:41. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112923.","journal-title":"Eur J Med Chem"},{"issue":"3","key":"3605_CR30","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2174\/0113892037332139241008054602","volume":"26","author":"F Belani","year":"2025","unstructured":"Belani F, Mehrabi M, Adibi H, Mehrabi M, Khodarahmi R. Discovery of Sulfanilamide-diazo Derivatives Incorporating Benzoic Acid Moieties as Novel Inhibitors of Human Carbonic Anhydrase II Activity. Curr Protein Pept Sci. 2025;26(3):226\u201340. https:\/\/doi.org\/10.2174\/0113892037332139241008054602.","journal-title":"Curr Protein Pept Sci"},{"key":"3605_CR31","doi-asserted-by":"publisher","unstructured":"Fujita N, Bondoc A, Simoes S, Ishida J, Taccone M, Luck A, et al. Combination treatment with histone deacetylase and carbonic anhydrase 9 inhibitors shows therapeutic potential in experimental diffuse intrinsic pontine glioma. Brain Tumor Pathol. 2024;15. https:\/\/doi.org\/10.1007\/s10014-024-00493-w.","DOI":"10.1007\/s10014-024-00493-w"},{"key":"3605_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijbiomac.2025.140462","volume":"303","author":"M Elkotamy","year":"2025","unstructured":"Elkotamy M, Abdelrahman M, Giovannuzzi S, Alkabbani M, Nocentini A, Supuran C, et al. Development of pyrazolo 1,5-a pyrimidine-grafted coumarins as selective carbonic anhydrase inhibitors and tubulin polymerization inhibitors with potent anticancer activity. Int J Biol Macromol. 2025;303:21. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.140462.","journal-title":"Int J Biol Macromol"},{"issue":"6","key":"3605_CR33","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2174\/0118715206341087241029064945","volume":"25","author":"P Singh","year":"2025","unstructured":"Singh P, Nerella S, Swain B, Angeli A, Kausar S, Ullah Q, et al. Synthesis of Chromene-linked Bis-indole Derivatives as Selective Tumor-associated Carbonic Anhydrase IX Inhibitors. Anti-Cancer Agents Med Chem. 2025;25(6):399\u2013410. https:\/\/doi.org\/10.2174\/0118715206341087241029064945.","journal-title":"Anti-Cancer Agents Med Chem"},{"key":"3605_CR34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.molstruc.2022.134767","volume":"1276","author":"N Zahedi","year":"2023","unstructured":"Zahedi N, Mohammadi-Khanaposhtani M, Rezaei P, Askarzadeh M, Alikhani M, Adib M, et al. Dual functional cholinesterase and carbonic anhydrase inhibitors for the treatment of Alzheimer\u2019s disease: Design, synthesis, in vitro, and in silico evaluations of coumarin-dihydropyridine derivatives. J Mol Struct. 2023;1276:12. https:\/\/doi.org\/10.1016\/j.molstruc.2022.134767.","journal-title":"J Mol Struct"},{"issue":"6","key":"3605_CR35","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1002\/bab.2780","volume":"72","author":"C \u00d6zt\u00fcrk","year":"2025","unstructured":"\u00d6zt\u00fcrk C, Balci N, Aslan O, Kalay E. Novel Sulfonylhydrazones With Sulfonate Ester Framework: Promising Dual Inhibitors of AChE and hCAs. Biotechnol Appl Biochem. 2025;72(6):1752\u201362. https:\/\/doi.org\/10.1002\/bab.2780.","journal-title":"Biotechnol Appl Biochem"},{"key":"3605_CR36","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1016\/j.ijbiomac.2020.09.043","volume":"163","author":"B Sever","year":"2020","unstructured":"Sever B, T\u00fcrkes C, Altintop M, Demir Y, Beydemir S. Thiazolyl-pyrazoline derivatives: In vitro and in silico evaluation as potential acetylcholinesterase and carbonic anhydrase inhibitors. Int J Biol Macromol. 2020;163:1970\u201388. https:\/\/doi.org\/10.1016\/j.ijbiomac.2020.09.043.","journal-title":"Int J Biol Macromol"},{"key":"3605_CR37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.molstruc.2025.144615","volume":"1353","author":"S \u00dcnl\u00fc","year":"2026","unstructured":"\u00dcnl\u00fc S, K\u00f6ksal Z, Kirboga K, Elmali F. Axially quinoline-substituted silicon phthalocyanines: Synthesis, characterization, molecular modeling and biological evaluation against cholinesterases and carbonic anhydrases. J Mol Struct. 2026;1353:8. https:\/\/doi.org\/10.1016\/j.molstruc.2025.144615.","journal-title":"J Mol Struct"},{"issue":"3","key":"3605_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/ardp.202000282","volume":"354","author":"M Kalayci","year":"2021","unstructured":"Kalayci M, T\u00fcrkes C, Arslan M, Demir Y, Beydemir S. Novel benzoic acid derivatives: Synthesis and biological evaluation as multitarget acetylcholinesterase and carbonic anhydrase inhibitors. Arch Pharm. 2021;354(3):17. https:\/\/doi.org\/10.1002\/ardp.202000282.","journal-title":"Arch Pharm"},{"issue":"19","key":"3605_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/slct.202304440","volume":"9","author":"E Karaca","year":"2024","unstructured":"Karaca E, G\u00fcrb\u00fcz N, Demir Y, T\u00fcz\u00fcn B, \u00d6zdemir I, Gulcin I. Synthesis of 1,3-Disubtitituted Tetrahydropyrimidinium Salts and Determination of Their Biological Properties and Molecular Docking. ChemistrySelect. 2024;9(19):11. https:\/\/doi.org\/10.1002\/slct.202304440.","journal-title":"ChemistrySelect"},{"issue":"1","key":"3605_CR40","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/bab.2329","volume":"70","author":"H Duran","year":"2023","unstructured":"Duran H, Pyrimidines. Molecular docking and inhibition studies on carbonic anhydrase and cholinesterases. Biotechnol Appl Biochem. 2023;70(1):68\u201382. https:\/\/doi.org\/10.1002\/bab.2329.","journal-title":"Biotechnol Appl Biochem"},{"issue":"7","key":"3605_CR41","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/aoc.70258","volume":"39","author":"\u00d6 Demirci","year":"2025","unstructured":"Demirci \u00d6, Demir Y, G\u00f6k Y, Yakali G, Taskin-Tok T, Muhammed M, et al. Imidazol-2-Ylidene-Silver(I) Complexes Bearing 4-Acetylphenyl Side Arm: Design, Synthesis, Characterization, Crystal Structure, and Inhibitory Properties Against Some Metabolic Enzymes. Appl Organomet Chem. 2025;39(7):22. https:\/\/doi.org\/10.1002\/aoc.70258.","journal-title":"Appl Organomet Chem"},{"issue":"8","key":"3605_CR42","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1021\/cr200176r","volume":"112","author":"V Alterio","year":"2012","unstructured":"Alterio V, Di Fiore A, D\u2019Ambrosio K, Supuran CT, De Simone G. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev. 2012;112(8):4421\u201368.","journal-title":"Chem Rev"},{"issue":"3","key":"3605_CR43","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00449-021-02667-8","volume":"45","author":"S Iraninasab","year":"2022","unstructured":"Iraninasab S, Sharifian S, Homaei A, Homaee M, Sharma T, Nadda A, et al. Emerging trends in environmental and industrial applications of marine carbonic anhydrase: a review. Bioprocess Biosyst Eng. 2022;45(3):431\u201351. https:\/\/doi.org\/10.1007\/s00449-021-02667-8.","journal-title":"Bioprocess Biosyst Eng"},{"issue":"48","key":"3605_CR44","doi-asserted-by":"publisher","first-page":"35769","DOI":"10.1039\/d4ra06290f","volume":"14","author":"N Naeem","year":"2024","unstructured":"Naeem N, Sadiq A, Othman G, Yassin H, Mughal E. Exploring heterocyclic scaffolds in carbonic anhydrase inhibition: a decade of structural and therapeutic insights. RSC Adv. 2024;14(48):35769\u2013970. https:\/\/doi.org\/10.1039\/d4ra06290f.","journal-title":"RSC Adv"},{"issue":"52","key":"3605_CR45","doi-asserted-by":"publisher","first-page":"85861","DOI":"10.18632\/oncotarget.13040","volume":"7","author":"J Kopecka","year":"2016","unstructured":"Kopecka J, Rankin G, Salaroglio I, Poulsen S, Riganti C. P-glycoprotein-mediated chemoresistance is reversed by carbonic anhydrase XII inhibitors. Oncotarget. 2016;7(52):85861\u201375. https:\/\/doi.org\/10.18632\/oncotarget.13040.","journal-title":"Oncotarget"},{"issue":"1","key":"3605_CR46","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1021\/ar7000843","volume":"41","author":"B Meunier","year":"2008","unstructured":"Meunier B. Hybrid molecules with a dual mode of action: Dream or reality? Acc Chem Res. 2008;41(1):69\u201377. https:\/\/doi.org\/10.1021\/ar7000843.","journal-title":"Acc Chem Res"},{"issue":"1","key":"3605_CR47","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1080\/14756366.2021.1945049","volume":"36","author":"C Supuran","year":"2021","unstructured":"Supuran C. Multitargeting approaches involving carbonic anhydrase inhibitors: hybrid drugs against a variety of disorders. J Enzym Inhib Med Chem. 2021;36(1):1702\u201314. https:\/\/doi.org\/10.1080\/14756366.2021.1945049.","journal-title":"J Enzym Inhib Med Chem"},{"issue":"4","key":"3605_CR48","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/cells8040350","volume":"8","author":"M Abbas","year":"2019","unstructured":"Abbas M, Kausar S, Wang F, Zhao Y, Cui H. Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators as a Therapy for Glioblastoma. Cells. 2019;8(4):22. https:\/\/doi.org\/10.3390\/cells8040350.","journal-title":"Cells"},{"key":"3605_CR49","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.bioorg.2026.109486","volume":"170","author":"S Ewieda","year":"2026","unstructured":"Ewieda S, Ahmed E, Halim P, Ibrahim S, Gouda K, Abdalla M, et al. Discovery of novel pyridazinone derivatives as EGFRWT\/ EGFRT790M kinase inhibitors; design, synthesis, antitumor evaluation, and molecular dynamic simulations. Bioorg Chem. 2026;170:18. https:\/\/doi.org\/10.1016\/j.bioorg.2026.109486.","journal-title":"Bioorg Chem"},{"issue":"1","key":"3605_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/emm.2004.1","volume":"36","author":"J Lee","year":"2004","unstructured":"Lee J, Bae S, Jeong J, Kim S, Kim K. Hypoxia-inducible factor (HIF-1)\u03b1: its protein stability and biological functions. Exp Mol Med. 2004;36(1):1\u201312. https:\/\/doi.org\/10.1038\/emm.2004.1.","journal-title":"Exp Mol Med"},{"issue":"3","key":"3605_CR51","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2174\/1568009611313030003","volume":"13","author":"F Agani","year":"2013","unstructured":"Agani F, Jiang B-H. Oxygen-independent regulation of HIF-1: novel involvement of PI3K\/AKT\/mTOR pathway in cancer. Curr Cancer Drug Targets. 2013;13(3):245\u201351. https:\/\/doi.org\/10.2174\/1568009611313030003.","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"3605_CR52","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8(1):23. https:\/\/doi.org\/10.1038\/s41392-023-01332-8.","journal-title":"Signal Transduct Target Ther"},{"key":"3605_CR53","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.semcancer.2022.01.001","volume":"86","author":"A Queen","year":"2022","unstructured":"Queen A, Bhutto H, Yousuf M, Syed M, Hassan M. Carbonic anhydrase IX: A tumor acidification switch in heterogeneity and chemokine regulation. Semin Cancer Biol. 2022;86:899\u2013913. https:\/\/doi.org\/10.1016\/j.semcancer.2022.01.001.","journal-title":"Semin Cancer Biol"},{"key":"3605_CR54","doi-asserted-by":"publisher","first-page":"113300","DOI":"10.1016\/j.ejmech.2021.113300","volume":"216","author":"B Zhang","year":"2021","unstructured":"Zhang B, Liu Z, Xia S, Liu Q, Gou S. Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR\/CAIX dual inhibitors. Eur J Med Chem. 2021;216:113300. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113300.","journal-title":"Eur J Med Chem"},{"key":"3605_CR55","doi-asserted-by":"publisher","first-page":"135010","DOI":"10.1016\/j.ijbiomac.2024.135010","volume":"279","author":"WM Eldehna","year":"2024","unstructured":"Eldehna WM, Elsayed ZM, Ammara A, El Hassab MA, Almahli H, Fares M, et al. Discovery of new sulfonamide-tethered 2-aryl-4-anilinoquinazolines as the first-in-class dual carbonic anhydrase and EGFR inhibitors. Int J Biol Macromol. 2024;279:135010. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.135010.","journal-title":"Int J Biol Macromol"},{"issue":"6","key":"3605_CR56","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1021\/cb500129t","volume":"9","author":"Z Zhao","year":"2014","unstructured":"Zhao Z, Wu H, Wang L, Liu Y, Knapp S, Liu Q, et al. Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? ACS Chem Biol. 2014;9(6):1230\u201341. https:\/\/doi.org\/10.1021\/cb500129t.","journal-title":"ACS Chem Biol"},{"issue":"16","key":"3605_CR57","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1016\/j.bmc.2016.05.063","volume":"24","author":"S Mowafy","year":"2016","unstructured":"Mowafy S, Galanis A, Doctor Z, Paranal R, Lasheen D, Farag N, et al. Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives. Bioorg Med Chem. 2016;24(16):3501\u201312. https:\/\/doi.org\/10.1016\/j.bmc.2016.05.063.","journal-title":"Bioorg Med Chem"},{"issue":"6","key":"3605_CR58","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/bf00124317","volume":"9","author":"P Furet","year":"1995","unstructured":"Furet P, Caravatti G, Lydon N, Priestle J, Sowadski J, Trinks U, et al. Modelling study of protein kinase inhibitors: Binding mode of staurosporine and origin of the selectivity of CGP 52411. J Comput-Aided Mol Des. 1995;9(6):465\u201372. https:\/\/doi.org\/10.1007\/bf00124317.","journal-title":"J Comput-Aided Mol Des"},{"key":"3605_CR59","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/srep16750","volume":"5","author":"V Gandin","year":"2015","unstructured":"Gandin V, Ferrarese A, Dalla Via M, Marzano C, Chilin A, Marzaro G. Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N\u2032- 4-(pyrimidin-4-ylamino)phenyl urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily. Sci Rep. 2015;5:16. https:\/\/doi.org\/10.1038\/srep16750.","journal-title":"Sci Rep"},{"issue":"7","key":"3605_CR60","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nchembio799","volume":"2","author":"Y Liu","year":"2006","unstructured":"Liu Y, Gray N. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol. 2006;2(7):358\u201364. https:\/\/doi.org\/10.1038\/nchembio799.","journal-title":"Nat Chem Biol"},{"key":"3605_CR61","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.bioorg.2019.103557","volume":"95","author":"S Ghorai","year":"2020","unstructured":"Ghorai S, Pulya S, Ghosh K, Panda P, Ghosh B, Gayen S. Structure-activity relationship of human carbonic anhydrase-II inhibitors: Detailed insight for future development as anti-glaucoma agents. Bioorg Chem. 2020;95:34. https:\/\/doi.org\/10.1016\/j.bioorg.2019.103557.","journal-title":"Bioorg Chem"},{"issue":"9","key":"3605_CR62","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/17568919.2025.2498879","volume":"17","author":"I Eissa","year":"2025","unstructured":"Eissa I, Elkady H, Elgammal W, Mahdy H, Elshennawy H, Husein D, et al. Development of new anticancer thiadiazole-sulfonamides as dual EGFR\/carbonic anhydrase inhibitors. Future Med Chem. 2025;17(9):1023\u201338. https:\/\/doi.org\/10.1080\/17568919.2025.2498879.","journal-title":"Future Med Chem"},{"issue":"9","key":"3605_CR63","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1371\/journal.pone.0328305","volume":"20","author":"I Eissa","year":"2025","unstructured":"Eissa I, Elkady H, Elgammal W, Mahdy H, Husein D, Amin F, et al. A novel sulfamoylphenyl-dihydro-thiadiazole derivative as a dual EGFR and carbonic anhydrase inhibitor for cancer therapy. PLoS ONE. 2025;20(9):36. https:\/\/doi.org\/10.1371\/journal.pone.0328305.","journal-title":"PLoS ONE"},{"issue":"6","key":"3605_CR64","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/17475198251400403","volume":"49","author":"E Elkaeed","year":"2025","unstructured":"Elkaeed E, Elkady H, Elgammal W, Mahdy H, Husein D, Ibrahim I, et al. A novel thiadiazole-based dual inhibitor of carbonic anhydrase-IX and epidermal growth factor receptor targeting cancer: A combined in silico and in vitro approach. J Chem Res. 2025;49(6):14. https:\/\/doi.org\/10.1177\/17475198251400403.","journal-title":"J Chem Res"},{"issue":"13","key":"3605_CR65","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1177\/1535370220934038","volume":"245","author":"S Roy","year":"2020","unstructured":"Roy S, Kumaravel S, Sharma A, Duran C, Bayless K, Chakraborty S. Hypoxic tumor microenvironment: Implications for cancer therapy. Exp Biol Med. 2020;245(13):1073\u201386. https:\/\/doi.org\/10.1177\/1535370220934038.","journal-title":"Exp Biol Med"},{"issue":"5","key":"3605_CR66","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/iep.12485","volume":"104","author":"W Zhang","year":"2023","unstructured":"Zhang W, Sun L, Gao H, Wang S. Mechanism of the HIF-1\u03b1\/VEGF\/VEGFR-2 pathway in the proliferation and apoptosis of human haemangioma endothelial cells. Int J Exp Pathol. 2023;104(5):258\u201368. https:\/\/doi.org\/10.1111\/iep.12485.","journal-title":"Int J Exp Pathol"},{"key":"3605_CR67","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.bioorg.2025.109157","volume":"166","author":"S Ewieda","year":"2025","unstructured":"Ewieda S, Ahmed E, Gohar N, Ibrahim S, Essa M, Nemr M. Design, synthesis, and antitumor evaluation of new pyridazinone scaffolds as dual EGFR\/VEGFR-2 kinase inhibitors and apoptotic cells inducers. Bioorg Chem. 2025;166:15. https:\/\/doi.org\/10.1016\/j.bioorg.2025.109157.","journal-title":"Bioorg Chem"},{"issue":"15","key":"3605_CR68","doi-asserted-by":"publisher","first-page":"10558","DOI":"10.1021\/acs.jmedchem.3c00721","volume":"66","author":"A Elsawi","year":"2023","unstructured":"Elsawi A, Elbadawi M, Nocentini A, Almahli H, Giovannuzzi S, Shaldam M, et al. 1,5-Diaryl-1,2,4-triazole Ureas as New SLC-0111 Analogues Endowed with Dual Carbonic Anhydrase and VEGFR-2 Inhibitory Activities. J Med Chem. 2023;66(15):10558\u201378. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00721.","journal-title":"J Med Chem"},{"issue":"1","key":"3605_CR69","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41598-024-62864-9","volume":"14","author":"H Abbas","year":"2024","unstructured":"Abbas H, Nossier E, El-Manawaty M, El-Bayaa M. New sulfonamide-based glycosides incorporated 1,2,3-triazole as cytotoxic agents through VEGFR-2 and carbonic anhydrase inhibitory activity. Sci Rep. 2024;14(1):16. https:\/\/doi.org\/10.1038\/s41598-024-62864-9.","journal-title":"Sci Rep"},{"key":"3605_CR70","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejmech.2023.115707","volume":"259","author":"S Saied","year":"2023","unstructured":"Saied S, Shaldam M, Elbadawi M, Giovannuzzi S, Nocentini A, Almahli H, et al. Discovery of indolinone-bearing benzenesulfonamides as new dual carbonic anhydrase and VEGFR-2 inhibitors possessing anticancer and pro-apoptotic properties. Eur J Med Chem. 2023;259:14. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115707.","journal-title":"Eur J Med Chem"},{"issue":"8","key":"3605_CR71","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/ddr.70030","volume":"85","author":"M Zengin","year":"2024","unstructured":"Zengin M, Tan O, Sabuncuoglu S, Arafa R, Balkan A. Design and Discovery of New Dual Carbonic Anhydrase IX and VEGFR-2 Inhibitors Based on the Benzenesulfonamide-Bearing 4-Thiazolidinones\/2,4-Thiazolidinediones Scaffold. Drug Dev Res. 2024;85(8):18. https:\/\/doi.org\/10.1002\/ddr.70030.","journal-title":"Drug Dev Res"},{"issue":"9","key":"3605_CR72","doi-asserted-by":"publisher","first-page":"7406","DOI":"10.1021\/acs.jmedchem.4c00239","volume":"67","author":"S Hefny","year":"2024","unstructured":"Hefny S, El-Moselhy T, El-Din N, Giovannuzzi S, Bin Traiki T, Vaali-Mohammed M, et al. Discovery and Mechanistic Studies of Dual-Target Hits for Carbonic Anhydrase IX and VEGFR-2 as Potential Agents for Solid Tumors: X-ray, In Vitro, In Vivo, and In Silico Investigations of Coumarin-Based Thiazoles. J Med Chem. 2024;67(9):7406\u201330. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00239.","journal-title":"J Med Chem"},{"issue":"2","key":"3605_CR73","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1039\/d5md01043h","volume":"17","author":"W Eldehna","year":"2026","unstructured":"Eldehna W, Elsayed Z, Elnagar M, Ammara A, Elkotamy M, Monir R, et al. Discovery of enaminone-linked benzofuran derivatives as dual VEGFR-2\/hCA IX inhibitors exhibiting hypoxia-mediated chemosensitization. RSC Med Chem. 2026;17(2):965\u201386. https:\/\/doi.org\/10.1039\/d5md01043h.","journal-title":"RSC Med Chem"},{"issue":"21","key":"3605_CR74","doi-asserted-by":"publisher","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","volume":"63","author":"T Ho","year":"2020","unstructured":"Ho T, Chan A, Ganesan A. Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight. J Med Chem. 2020;63(21):12460\u201384. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00830.","journal-title":"J Med Chem"},{"issue":"6","key":"3605_CR75","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.drudis.2015.01.007","volume":"20","author":"C Micelli","year":"2015","unstructured":"Micelli C, Rastelli G. Histone deacetylases: structural determinants of inhibitor selectivity. Drug Discov Today. 2015;20(6):718\u201335. https:\/\/doi.org\/10.1016\/j.drudis.2015.01.007.","journal-title":"Drug Discov Today"},{"issue":"2\u20133","key":"3605_CR76","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ejcb.2004.12.010","volume":"84","author":"H Hess-Stumpp","year":"2005","unstructured":"Hess-Stumpp H. Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur J Cell Biol. 2005;84(2\u20133):109\u201321. https:\/\/doi.org\/10.1016\/j.ejcb.2004.12.010.","journal-title":"Eur J Cell Biol"},{"issue":"3","key":"3605_CR77","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/sj.cr.7310149","volume":"17","author":"P Gallinari","year":"2007","unstructured":"Gallinari P, Di Marco S, Jones P, Pallaoro M, Steink\u00fchler C. HDACs, histone deacetylation and gene transcription:: from molecular biology to cancer therapeutics. Cell Res. 2007;17(3):195\u2013211. https:\/\/doi.org\/10.1038\/sj.cr.7310149.","journal-title":"Cell Res"},{"key":"3605_CR78","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bioorg.2025.108694","volume":"163","author":"M Mohamed","year":"2025","unstructured":"Mohamed M, Salem I, Fouad A, Allam R, Fadaly W, Nemr M, et al. Synthesis and apoptotic induction of sulfonamide-based chalcone hybrids as first-in-class dual histone deacetylase-carbonic anhydrase inhibitors with potential anti-tubulin activity. Bioorg Chem. 2025;163:22. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108694.","journal-title":"Bioorg Chem"},{"issue":"42","key":"3605_CR79","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/slct.202504601","volume":"10","author":"M Nemr","year":"2025","unstructured":"Nemr M, Fadaly W, Abdelaziz M. Pharmaceutical Applications of Di\/Tri-Aryl Pyrazole Derivatives: A Review on Recent Updates. ChemistrySelect. 2025;10(42):25. https:\/\/doi.org\/10.1002\/slct.202504601.","journal-title":"ChemistrySelect"},{"issue":"24","key":"3605_CR80","first-page":"7075","volume":"60","author":"C Wykoff","year":"2000","unstructured":"Wykoff C, Beasley N, Watson P, Turner K, Pastorek J, Sibtain A, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000;60(24):7075\u201383.","journal-title":"Cancer Res"},{"issue":"10","key":"3605_CR81","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/cells14100693","volume":"14","author":"H Yang","year":"2025","unstructured":"Yang H, Chen R, Zheng X, Luo Y, Yao M, Ke F, et al. Cooperative Role of Carbonic Anhydrase IX\/XII in Driving Tumor Invasion and Metastasis: A Novel Targeted Therapeutic Strategy. Cells. 2025;14(10):24. https:\/\/doi.org\/10.3390\/cells14100693.","journal-title":"Cells"},{"issue":"21","key":"3605_CR82","doi-asserted-by":"publisher","first-page":"22874","DOI":"10.1021\/acs.jmedchem.5c01788","volume":"68","author":"M Bozdag","year":"2025","unstructured":"Bozdag M, Mroweh N, Raucci A, Angeli A, Peppicelli S, Biagioni A, et al. Discovery of First-in-Class Carbonic Anhydrase\/Histone Deacetylase Dual Inhibitors with Antiproliferative Activity in Cancer Cells. J Med Chem. 2025;68(21):22874\u201395. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c01788.","journal-title":"J Med Chem"},{"issue":"22","key":"3605_CR83","doi-asserted-by":"publisher","first-page":"12483","DOI":"10.1093\/nar\/gkaa1002","volume":"48","author":"S Hume","year":"2020","unstructured":"Hume S, Dianov G, Ramadan K. A unified model for the G1\/S cell cycle transition. Nucleic Acids Res. 2020;48(22):12483\u2013501. https:\/\/doi.org\/10.1093\/nar\/gkaa1002.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"3605_CR84","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41392-024-02080-z","volume":"10","author":"I Pellarin","year":"2025","unstructured":"Pellarin I, Dall\u2019Acqua A, Favero A, Segatto I, Rossi V, Crestan N, et al. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduct Target Ther. 2025;10(1):62. https:\/\/doi.org\/10.1038\/s41392-024-02080-z.","journal-title":"Signal Transduct Target Ther"},{"key":"3605_CR85","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.critrevonc.2024.104324","volume":"196","author":"R Gerosa","year":"2024","unstructured":"Gerosa R, De Sanctis R, Jacobs F, Benvenuti C, Gaudio M, Saltalamacchia G, et al. Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions. Crit Rev Oncol\/Hematol. 2024;196:11. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104324.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"15","key":"3605_CR86","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/slct.202500175","volume":"10","author":"M Abdalla","year":"2025","unstructured":"Abdalla M, Elmasry A, Nemr M, Alanazi M, Attallah N, Elshaier Y. Insight Study For Repurposing Of Certain Anti-Inflammatory Drugs Based On Aspirin and Salicylic Acid Scaffolds For The Treatment of Cancer as CDKs Inhibitors: Cheminformatics and Anticancer Studies. ChemistrySelect. 2025;10(15):21. https:\/\/doi.org\/10.1002\/slct.202500175.","journal-title":"ChemistrySelect"},{"issue":"10","key":"3605_CR87","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3978\/j.issn.2305-5839.2015.03.61","volume":"3","author":"J Cicenas","year":"2015","unstructured":"Cicenas J, Kalyan K, Sorokinas A, Stankunas E, Levy J, Meskinyte I, et al. Roscovitine in cancer and other diseases. Annals translational Med. 2015;3(10):135. https:\/\/doi.org\/10.3978\/j.issn.2305-5839.2015.03.61.","journal-title":"Annals translational Med"},{"issue":"5","key":"3605_CR88","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/ddr.70139","volume":"86","author":"K Anwer","year":"2025","unstructured":"Anwer K, El-Dydamony N, Saleh A, Altwaijry N, Husseiny E. Comparative Study of Conventional, Grinding, and Microwave-Assisted Synthesis of Aminopyrazolones and Diaminopyrazoles: Exploring the Antitumor Activity, Dual CDK-2\/CA IX Inhibition Potential, and Apoptosis Induction. Drug Dev Res. 2025;86(5):22. https:\/\/doi.org\/10.1002\/ddr.70139.","journal-title":"Drug Dev Res"},{"key":"3605_CR89","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ejmech.2025.117752","volume":"293","author":"M Elkotamy","year":"2025","unstructured":"Elkotamy M, Elkelesh I, Giovannuzzi S, Ismail R, El-Refaie W, Almehizia A, et al. Rationally designed Pyrazolo 1,5-a pyrimidines as dual inhibitors of CA IX\/XII and CDK6: A novel approach for NSCLC treatment. Eur J Med Chem. 2025;293:16. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117752.","journal-title":"Eur J Med Chem"},{"key":"3605_CR90","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.bioorg.2025.109057","volume":"166","author":"H Abosalim","year":"2025","unstructured":"Abosalim H, El-Moselhy T, Sharafeldin N, Giovannuzzi S, Begines P, Nafie M, et al. Innovative design and synthesis of dual-acting hCA IX\/CDK-2 inhibitors through hetero ring fused pyrimidine utilization for cutting-edge anticancer therapy: Zein nanoparticles for in vivo lung cancer treatment. Bioorg Chem. 2025;166:27. https:\/\/doi.org\/10.1016\/j.bioorg.2025.109057.","journal-title":"Bioorg Chem"},{"issue":"1","key":"3605_CR91","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/5289","volume":"17","author":"A Persidis","year":"1999","unstructured":"Persidis A. Cancer multidrug resistance. Nat Biotechnol. 1999;17(1):94\u20135. https:\/\/doi.org\/10.1038\/5289.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"3605_CR92","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3892\/ijo.2023.5567","volume":"63","author":"Y Tian","year":"2023","unstructured":"Tian Y, Lei Y, Wang Y, Lai J, Wang J, Xia F. Mechanism of multidrug resistance to chemotherapy mediated by P-glycoprotein (Review). Int J Oncol. 2023;63(5):19. https:\/\/doi.org\/10.3892\/ijo.2023.5567.","journal-title":"Int J Oncol"},{"issue":"10","key":"3605_CR93","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s41571-025-01059-1","volume":"22","author":"M Ge","year":"2025","unstructured":"Ge M, Chen X, Huang P, Fleishman J, Yang D, Wu Z, et al. Understanding and overcoming multidrug resistance in cancer. Nat Rev Clin Oncol. 2025;22(10):760\u201380. https:\/\/doi.org\/10.1038\/s41571-025-01059-1.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1\u20132","key":"3605_CR94","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10555-019-09799-0","volume":"38","author":"S Pastorekova","year":"2019","unstructured":"Pastorekova S, Gillies R. The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond. Cancer Metastasis Rev. 2019;38(1\u20132):65\u201377. https:\/\/doi.org\/10.1007\/s10555-019-09799-0.","journal-title":"Cancer Metastasis Rev"},{"issue":"12","key":"3605_CR95","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1080\/13543784.2018.1548608","volume":"27","author":"C Supuran","year":"2018","unstructured":"Supuran C. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs. 2018;27(12):963\u201370. https:\/\/doi.org\/10.1080\/13543784.2018.1548608.","journal-title":"Expert Opin Investig Drugs"},{"issue":"10","key":"3605_CR96","doi-asserted-by":"publisher","first-page":"4258","DOI":"10.1002\/jps.22596","volume":"100","author":"P Mitra","year":"2011","unstructured":"Mitra P, Audus K, Williams G, Yazdanian M, Galinis D. A Comprehensive Study Demonstrating That P-glycoprotein Function Is Directly Affected by Changes in pH: Implications for Intestinal pH and Effects on Drug Absorption. J Pharm Sci. 2011;100(10):4258\u201368. https:\/\/doi.org\/10.1002\/jps.22596.","journal-title":"J Pharm Sci"},{"issue":"7","key":"3605_CR97","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/molecules25071748","volume":"25","author":"E Teodori","year":"2020","unstructured":"Teodori E, Braconi L, Bua S, Lapucci A, Bartolucci G, Manetti D, et al. Dual P-Glycoprotein and CA XII Inhibitors: A New Strategy to Reverse the P-gp Mediated Multidrug Resistance (MDR) in Cancer Cells. Molecules. 2020;25(7):26. https:\/\/doi.org\/10.3390\/molecules25071748.","journal-title":"Molecules"},{"issue":"21","key":"3605_CR98","doi-asserted-by":"publisher","first-page":"14655","DOI":"10.1021\/acs.jmedchem.2c01175","volume":"65","author":"L Braconi","year":"2022","unstructured":"Braconi L, Teodori E, Riganti C, Coronnello M, Nocentini A, Bartolucci G, et al. New Dual P-Glycoprotein (P-gp) and Human Carbonic Anhydrase XII (hCA XII) Inhibitors as Multidrug Resistance (MDR) Reversers in Cancer Cells. J Med Chem. 2022;65(21):14655\u201372. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01175.","journal-title":"J Med Chem"},{"issue":"14","key":"3605_CR99","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/molecules29143290","volume":"29","author":"L Braconi","year":"2024","unstructured":"Braconi L, Riganti C, Parenti A, Cecchi M, Nocentini A, Bartolucci G, et al. Dual Inhibitors of P-gp and Carbonic Anhydrase XII (hCA XII) against Tumor Multidrug Resistance with Piperazine Scaffold. Molecules. 2024;29(14):32. https:\/\/doi.org\/10.3390\/molecules29143290.","journal-title":"Molecules"},{"key":"3605_CR100","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejps.2019.105012","volume":"138","author":"A Podolski-Renic","year":"2019","unstructured":"Podolski-Renic A, Dinic J, Stankovic T, Jovanovic M, Ramovic A, Pustenko A, et al. Sulfocoumarins, specific carbonic anhydrase IX and XII inhibitors, interact with cancer multidrug resistant phenotype through pH regulation and reverse P-glycoprotein mediated resistance. Eur J Pharm Sci. 2019;138:9. https:\/\/doi.org\/10.1016\/j.ejps.2019.105012.","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"3605_CR101","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cmdc.202500996","volume":"21","author":"M Puxeddu","year":"2026","unstructured":"Puxeddu M, Bordone R, Colla C, Rotili G, Coluccia A, Sci\u00f2 P, et al. 4-(5-Chloro-3-(3,4,5-trimethoxybenzoyl)-1H-indol-1-yl)benzenesulfonamide: A Novel Polypharmacology Agent to Target Carbonic Anhydrase IX and XII With Improved Selectivity, Wnt\/\u03b2-Catenin Signaling Pathway, and P-Glycoprotein. ChemMedChem. 2026;21(4):19. https:\/\/doi.org\/10.1002\/cmdc.202500996.","journal-title":"ChemMedChem"},{"key":"3605_CR102","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.canlet.2019.02.035","volume":"449","author":"O Mijanovic","year":"2019","unstructured":"Mijanovic O, Brankovic A, Panin A, Saychuk S, Timashev P, Ulasov I, et al. Cathepsin B: A sellsword of cancer progression. Cancer Lett. 2019;449:207\u201314. https:\/\/doi.org\/10.1016\/j.canlet.2019.02.035.","journal-title":"Cancer Lett"},{"key":"3605_CR103","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.bioorg.2023.106725","volume":"139","author":"M Abdoli","year":"2023","unstructured":"Abdoli M, Krasniqi V, Bonardi A, Guetschow M, Supuran C, Zalubovskis R. 4-Cyanamido-substituted benzenesulfonamides act as dual carbonic anhydrase and cathepsin inhibitors. Bioorg Chem. 2023;139:7. https:\/\/doi.org\/10.1016\/j.bioorg.2023.106725.","journal-title":"Bioorg Chem"},{"issue":"3","key":"3605_CR104","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/ardp.202300372","volume":"357","author":"K Siwach","year":"2024","unstructured":"Siwach K, Rani M, Vats L, Giovannuzzi S, Paul A, Brahma M, et al. 1,2,3-Triazole-based esters and carboxylic acids as nonclassical carbonic anhydrase inhibitors capable of cathepsin B inhibition. Arch Pharm. 2024;357(3):17. https:\/\/doi.org\/10.1002\/ardp.202300372.","journal-title":"Arch Pharm"},{"issue":"10","key":"3605_CR105","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/ardp.202400114","volume":"357","author":"K Siwach","year":"2024","unstructured":"Siwach K, Arya P, Vats L, Sharma V, Giovannuzzi S, Raghav N, et al. Benzenesulfonamides functionalized with triazolyl-linked pyrazoles possess dual cathepsin B and carbonic anhydrase inhibitory action. Arch Pharm. 2024;357(10):15. https:\/\/doi.org\/10.1002\/ardp.202400114.","journal-title":"Arch Pharm"},{"issue":"3","key":"3605_CR106","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.clcc.2018.02.013","volume":"17","author":"S Lee","year":"2018","unstructured":"Lee S, Lee J, Park S, Park J, Lim H, Kang W, et al. c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival. Clin Colorectal Canc. 2018;17(3):165\u20139. https:\/\/doi.org\/10.1016\/j.clcc.2018.02.013.","journal-title":"Clin Colorectal Canc"},{"key":"3605_CR107","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.semcancer.2014.08.002","volume":"31","author":"J Pastorek","year":"2015","unstructured":"Pastorek J, Pastorekova S. Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: From biology to clinical use. Semin Cancer Biol. 2015;31:52\u201364. https:\/\/doi.org\/10.1016\/j.semcancer.2014.08.002.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"3605_CR108","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10555-019-09799-0","volume":"38","author":"S Pastorekova","year":"2019","unstructured":"Pastorekova S, Gillies RJ. The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond. Cancer Metastasis Rev. 2019;38(1):65\u201377. https:\/\/doi.org\/10.1007\/s10555-019-09799-0.","journal-title":"Cancer Metastasis Rev"},{"key":"3605_CR109","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.bioorg.2025.109071","volume":"166","author":"W Eldehna","year":"2025","unstructured":"Eldehna W, Elnagar M, Giovannuzzi S, Tayel A, Abdulla M, Alhassan N, et al. Identification of isatin-triazole-benzenesulfonamide hybrids as dual hCA IX\/XII and c-met inhibitors with hypoxia-mediated chemo-sensitizing activity. Bioorg Chem. 2025;166:13. https:\/\/doi.org\/10.1016\/j.bioorg.2025.109071.","journal-title":"Bioorg Chem"},{"issue":"1","key":"3605_CR110","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12967-021-03021-y","volume":"19","author":"L Qiu","year":"2021","unstructured":"Qiu L, Ma Y, Chen X, Zhou L, Zhang H, Zhong G, et al. Heparin-binding growth factor (HDGF) drives radioresistance in breast cancer by activating the STAT3 signaling pathway. J Transl Med. 2021;19(1):10. https:\/\/doi.org\/10.1186\/s12967-021-03021-y.","journal-title":"J Transl Med"},{"issue":"16","key":"3605_CR111","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.2174\/0929867329666220819093117","volume":"30","author":"J Song","year":"2023","unstructured":"Song J, Wang J, Tian S, Li H. Discovery of STAT3 Inhibitors: Recent Advances and Future Perspectives. Curr Med Chem. 2023;30(16):1824\u201347. https:\/\/doi.org\/10.2174\/0929867329666220819093117.","journal-title":"Curr Med Chem"},{"issue":"9","key":"3605_CR112","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.tips.2024.07.003","volume":"45","author":"Z Wang","year":"2024","unstructured":"Wang Z, Liao X, He H, Guo X, Chen J. Targeting the STAT3 pathway with STAT3 degraders. Trends Pharmacol Sci. 2024;45(9):811\u201323. https:\/\/doi.org\/10.1016\/j.tips.2024.07.003.","journal-title":"Trends Pharmacol Sci"},{"issue":"13","key":"3605_CR113","doi-asserted-by":"publisher","first-page":"8884","DOI":"10.1021\/acs.jmedchem.1c00629","volume":"64","author":"J Dong","year":"2021","unstructured":"Dong J, Cheng X, Zhang W, Qin J. Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation. J Med Chem. 2021;64(13):8884\u2013915. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00629.","journal-title":"J Med Chem"},{"key":"3605_CR114","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13046-018-0992-z","volume":"37","author":"X Dai","year":"2018","unstructured":"Dai X, Yin C, Zhang Y, Guo G, Zhao C, Wang O, et al. Osthole inhibits triple negative breast cancer cells by suppressing STAT3. J Exp Clin Cancer Res. 2018;37:11. https:\/\/doi.org\/10.1186\/s13046-018-0992-z.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3605_CR115","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12964-020-0527-z","volume":"18","author":"J Ma","year":"2020","unstructured":"Ma J, Qin L, Li X. Role of STAT3 signaling pathway in breast cancer. Cell Commun Signal. 2020;18(1):13. https:\/\/doi.org\/10.1186\/s12964-020-0527-z.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"3605_CR116","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12967-024-05542-8","volume":"22","author":"R Zheng","year":"2024","unstructured":"Zheng R, Guan T, Hong C, Yao Y, Fang Y, Huang W, et al. C188-9 reduces patient-specific primary breast cancer cells proliferation at the low, clinic-relevant concentration. J Transl Med. 2024;22(1):9. https:\/\/doi.org\/10.1186\/s12967-024-05542-8.","journal-title":"J Transl Med"},{"issue":"13","key":"3605_CR117","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.2174\/0929867311320130009","volume":"20","author":"Z Chen","year":"2013","unstructured":"Chen Z, Han L, Xu M, Xu Y, Qian X. Rationally Designed Multitarget Anticancer Agents. Curr Med Chem. 2013;20(13):1694\u2013714. https:\/\/doi.org\/10.2174\/0929867311320130009.","journal-title":"Curr Med Chem"},{"key":"3605_CR118","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ejmech.2017.05.016","volume":"136","author":"R-g Fu","year":"2017","unstructured":"Fu R-g, Sun Y, Sheng W-b. Liao D-f. Designing multi-targeted agents: An emerging anticancer drug discovery paradigm. Eur J Med Chem. 2017;136:195\u2013211. https:\/\/doi.org\/10.1016\/j.ejmech.2017.05.016.","journal-title":"Eur J Med Chem"},{"issue":"6","key":"3605_CR119","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1021\/acs.jcim.9b00031","volume":"59","author":"D Shi","year":"2019","unstructured":"Shi D, Khan F, Abagyan R. Extended Multitarget Pharmacology of Anticancer Drugs. J Chem Inf Model. 2019;59(6):3006\u201317. https:\/\/doi.org\/10.1021\/acs.jcim.9b00031.","journal-title":"J Chem Inf Model"},{"issue":"7","key":"3605_CR120","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00706-024-03220-5","volume":"155","author":"Z Mao","year":"2024","unstructured":"Mao Z, Liu S, Chen X, Wei J, Huang R, Zhang Y. Synthesis and pharmacological evaluation of polyamine-diarylidenyl piperidone derivatives as potent antitumor agents. Mon Chem. 2024;155(7):747\u201353. https:\/\/doi.org\/10.1007\/s00706-024-03220-5.","journal-title":"Mon Chem"},{"key":"3605_CR121","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.bioorg.2022.106323","volume":"131","author":"S Liu","year":"2023","unstructured":"Liu S, Mao Z, Xu Y, Chen X, Wang H, Wang Q, et al. Discovery of two biotin-PEG4-diarylidenyl piperidone prodrugs as potent antitumor agents with good efficacy, limited toxicity, and low resistance. Bioorg Chem. 2023;131:10. https:\/\/doi.org\/10.1016\/j.bioorg.2022.106323.","journal-title":"Bioorg Chem"},{"issue":"12","key":"3605_CR122","doi-asserted-by":"publisher","first-page":"12493","DOI":"10.1021\/acs.jmedchem.5c00126","volume":"68","author":"L Chen","year":"2025","unstructured":"Chen L, Chen X, Mao Z, Gou Y, Ma X, Wei J, et al. Discovery of Diaryl Piperidone-Sulfonamide as a Novel Dual-Target Inhibitor of STAT3\/CAIX Inducing Ferroptosis in Triple-Negative Breast Cancer Cells. J Med Chem. 2025;68(12):12493\u2013512. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c00126.","journal-title":"J Med Chem"},{"issue":"12","key":"3605_CR123","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.cellsig.2009.06.002","volume":"21","author":"K Masson","year":"2009","unstructured":"Masson K, R\u00f6nnstrand L. Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. Cell Signal. 2009;21(12):1717\u201326. https:\/\/doi.org\/10.1016\/j.cellsig.2009.06.002.","journal-title":"Cell Signal"},{"issue":"11","key":"3605_CR124","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.3324\/haematol.2023.284524","volume":"109","author":"K Verhoeft","year":"2024","unstructured":"Verhoeft K, Cools J. The unexpected and unresolved roles of PDGFRA and PDGFRB in T-cell acute lymphoblastic leukemia. Haematologica. 2024;109(11):3461\u20132. https:\/\/doi.org\/10.3324\/haematol.2023.284524.","journal-title":"Haematologica"},{"issue":"24","key":"3605_CR125","doi-asserted-by":"publisher","first-page":"11039","DOI":"10.1111\/jcmm.17027","volume":"25","author":"F Chen","year":"2021","unstructured":"Chen F, Licarete E, Wu X, Petrusca D, Maguire C, Jacobsen M, et al. Pharmacological inhibition of Carbonic Anhydrase IX and XII to enhance targeting of acute myeloid leukaemia cells under hypoxic conditions. J Cell Mol Med. 2021;25(24):11039\u201352. https:\/\/doi.org\/10.1111\/jcmm.17027.","journal-title":"J Cell Mol Med"},{"issue":"23","key":"3605_CR126","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1182\/blood.V126.23.4822.4822","volume":"126","author":"K Nasu","year":"2015","unstructured":"Nasu K, Yamaguchi K, Takanashi Y, Sugamura K, Harigae H. Carbonic Anhydrase IX Promotes the Tumorigenicity of Adult T-Cell Leukemia\/Lymphoma-Derived Cells in NOG Mice. Blood. 2015;126(23):3. https:\/\/doi.org\/10.1182\/blood.V126.23.4822.4822.","journal-title":"Blood"},{"issue":"3","key":"3605_CR127","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1021\/acs.jmedchem.5c03037","volume":"69","author":"E Roshdy","year":"2026","unstructured":"Roshdy E, Rezn\u00edckov\u00e1 E, Elbadawi M, Celik I, Giovannuzzi S, Vesel\u00e1 D, et al. First-in-Class Dual PDGFR\/Carbonic Anhydrase IX\/XII Inhibitors: 6,7-Dimethoxyquinoline-Sulfonamides as Promising Antileukemic Agents. J Med Chem. 2026;69(3):3115\u201337. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c03037.","journal-title":"J Med Chem"},{"issue":"23","key":"3605_CR128","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/cmdc.202000594","volume":"15","author":"L Di Magno","year":"2020","unstructured":"Di Magno L, Di Pastena F, Puxeddu M, La Regina G, Coluccia A, Ciogli A, et al. Sulfonamide Inhibitors of \u03b2-Catenin Signaling as Anticancer Agents with Different Output on c-MYC. ChemMedChem. 2020;15(23):2264\u20138. https:\/\/doi.org\/10.1002\/cmdc.202000594.","journal-title":"ChemMedChem"},{"issue":"21","key":"3605_CR129","doi-asserted-by":"publisher","first-page":"14824","DOI":"10.1021\/acs.jmedchem.3c01424","volume":"66","author":"D Masci","year":"2023","unstructured":"Masci D, Puxeddu M, Di Magno L, D\u2019Ambrosio M, Parisi A, Nalli M, et al. 4-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1H-pyrrol-1-yl)benzenesulfonamide, a Novel Carbonic Anhydrase and Wnt\/\u03b2-Catenin Signaling Pathway Dual-Targeting Inhibitor with Potent Activity against Multidrug Resistant Cancer Cells. J Med Chem. 2023;66(21):14824\u201342. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c01424.","journal-title":"J Med Chem"},{"key":"3605_CR130","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12929-018-0422-8","volume":"25","author":"R Leao","year":"2018","unstructured":"Leao R, Apol\u00f3nio J, Lee D, Figueiredo A, Tabori U, Castelo-Branco P. Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer. J Biomed Sci. 2018;25:12. https:\/\/doi.org\/10.1186\/s12929-018-0422-8.","journal-title":"J Biomed Sci"},{"issue":"35","key":"3605_CR131","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/md.0000000000011794","volume":"97","author":"K Wang","year":"2018","unstructured":"Wang K, Wang R, Liu J, Zhou J, Li X, Hu W, et al. The prognostic significance of hTERT overexpression in cancers A systematic review and meta-analysis. Med (Baltim). 2018;97(35):8. https:\/\/doi.org\/10.1097\/md.0000000000011794.","journal-title":"Med (Baltim)"},{"issue":"3","key":"3605_CR132","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrc2275","volume":"8","author":"C Harley","year":"2008","unstructured":"Harley C. Telomerase and cancer therapeutics. Nat Rev Cancer. 2008;8(3):167\u201379. https:\/\/doi.org\/10.1038\/nrc2275.","journal-title":"Nat Rev Cancer"},{"key":"3605_CR133","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.biochi.2015.12.001","volume":"121","author":"K Terali","year":"2016","unstructured":"Terali K, Yilmazer A. New surprises from an old favourite: The emergence of telomerase as a key player in the regulation of cancer stemness. Biochimie. 2016;121:170\u20138. https:\/\/doi.org\/10.1016\/j.biochi.2015.12.001.","journal-title":"Biochimie"},{"issue":"9","key":"3605_CR134","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.tibs.2013.07.001","volume":"38","author":"K Low","year":"2013","unstructured":"Low K, Tergaonkar V. Telomerase: central regulator of all of the hallmarks of cancer. Trends BiochemSci. 2013;38(9):426\u201334. https:\/\/doi.org\/10.1016\/j.tibs.2013.07.001.","journal-title":"Trends BiochemSci"},{"issue":"10","key":"3605_CR135","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1080\/15476286.2015.1081329","volume":"12","author":"P Rousseau","year":"2015","unstructured":"Rousseau P, Autexier C. Telomere biology: Rationale for diagnostics and therapeutics in cancer. RNA Biol. 2015;12(10):1078\u201382. https:\/\/doi.org\/10.1080\/15476286.2015.1081329.","journal-title":"RNA Biol"},{"issue":"13","key":"3605_CR136","doi-asserted-by":"publisher","first-page":"7392","DOI":"10.1021\/acs.jmedchem.0c00636","volume":"63","author":"E Berrino","year":"2020","unstructured":"Berrino E, Angeli A, Zhdanov D, Kiryukhina A, Milaneschi A, De Luca A, et al. Azidothymidine Clicked into 1,2,3-Triazoles: First Report on Carbonic Anhydrase-Telomerase Dual-Hybrid Inhibitors. J Med Chem. 2020;63(13):7392\u2013409. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00636.","journal-title":"J Med Chem"},{"issue":"15","key":"3605_CR137","doi-asserted-by":"publisher","first-page":"11432","DOI":"10.1021\/acs.jmedchem.1c00756","volume":"64","author":"A Plyasova","year":"2021","unstructured":"Plyasova A, Berrino E, Khan I, Veselovsky A, Pokrovsky V, Angeli A, et al. Mechanisms of the Antiproliferative and Antitumor Activity of Novel Telomerase-Carbonic Anhydrase Dual-Hybrid Inhibitors. J Med Chem. 2021;64(15):11432\u201344. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00756.","journal-title":"J Med Chem"},{"issue":"45","key":"3605_CR138","doi-asserted-by":"publisher","first-page":"6244","DOI":"10.1038\/onc.2017.219","volume":"36","author":"M Swayampakula","year":"2017","unstructured":"Swayampakula M, McDonald P, Vallejo M, Coyaud E, Chafe S, Westerback A, et al. The interactome of metabolic enzyme carbonic anhydrase IX reveals novel roles in tumor cell migration and invadopodia\/MMP14-mediated invasion. Oncogene. 2017;36(45):6244\u201361. https:\/\/doi.org\/10.1038\/onc.2017.219.","journal-title":"Oncogene"},{"key":"3605_CR139","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejmech.2025.118107","volume":"300","author":"G Renzi","year":"2025","unstructured":"Renzi G, McDonald P, Awrey S, Tavakoli H, Bokhari Z, Lyle M, et al. Dual inhibition of carbonic anhydrase IX and glutathione peroxidase 4 as a novel strategy for ferroptosis-induced tumor cell death. Eur J Med Chem. 2025;300:27. https:\/\/doi.org\/10.1016\/j.ejmech.2025.118107.","journal-title":"Eur J Med Chem"},{"issue":"23","key":"3605_CR140","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.2174\/15680266113136660206","volume":"13","author":"C D\u00f6lle","year":"2013","unstructured":"D\u00f6lle C, Skoge R, VanLinden M, Ziegler M. NAD Biosynthesis in Humans - Enzymes, Metabolites and Therapeutic Aspects. Curr Top Med Chem. 2013;13(23):2907\u201317. https:\/\/doi.org\/10.2174\/15680266113136660206.","journal-title":"Curr Top Med Chem"},{"key":"3605_CR141","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.biocel.2022.106189","volume":"145","author":"M Gasparrini","year":"2022","unstructured":"Gasparrini M, Audrito V, NAMPT. A critical driver and therapeutic target for cancer. Int J Biochem Cell Biol. 2022;145:9. https:\/\/doi.org\/10.1016\/j.biocel.2022.106189.","journal-title":"Int J Biochem Cell Biol"},{"key":"3605_CR142","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fonc.2019.01514","volume":"9","author":"C Heske","year":"2020","unstructured":"Heske C. Beyond Energy Metabolism: Exploiting the Additional Roles of NAMPT for Cancer Therapy. Front Oncol. 2020;9:11. https:\/\/doi.org\/10.3389\/fonc.2019.01514.","journal-title":"Front Oncol"},{"key":"3605_CR143","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.metabol.2018.01.001","volume":"82","author":"M Dalamaga","year":"2018","unstructured":"Dalamaga M, Christodoulatos G, Mantzoros C. The role of extracellular and intracellular Nicotinamide phosphoribosyl-transferase in cancer: Diagnostic and therapeutic perspectives and challenges. Metab-Clin Exp. 2018;82:72\u201387. https:\/\/doi.org\/10.1016\/j.metabol.2018.01.001.","journal-title":"Metab-Clin Exp"},{"issue":"7","key":"3605_CR144","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1080\/13543776.2024.2367006","volume":"34","author":"M Gasparrini","year":"2024","unstructured":"Gasparrini M, Giovannuzzi S, Nocentini A, Raffaelli N, Supuran C. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review. Expert Opin Ther Pat. 2024;34(7):565\u201382. https:\/\/doi.org\/10.1080\/13543776.2024.2367006.","journal-title":"Expert Opin Ther Pat"},{"issue":"3","key":"3605_CR145","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1021\/acs.jmedchem.5c03157","volume":"69","author":"N Paoletti","year":"2026","unstructured":"Paoletti N, Giovannuzzi S, Gasparrini M, Ammara A, Zaroon Z, Raffaelli N, et al. Targeting Metabolic and pH Regulatory Pathways in Cancer via Dual Inhibition of Nicotinamide Phosphoribosyltransferase and Carbonic Anhydrases IX and XII. J Med Chem. 2026;69(3):3289\u2013314. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c03157.","journal-title":"J Med Chem"},{"issue":"9","key":"3605_CR146","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.tips.2017.06.001","volume":"38","author":"J Zhang","year":"2017","unstructured":"Zhang J, Li X, Han X, Liu R, Fang J. Targeting the Thioredoxin System for Cancer Therapy. Trends Pharmacol Sci. 2017;38(9):794\u2013808. https:\/\/doi.org\/10.1016\/j.tips.2017.06.001.","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"3605_CR147","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.semcancer.2006.10.009","volume":"16","author":"E Arn\u00e9r","year":"2006","unstructured":"Arn\u00e9r E, Holmgren A. The thioredoxin system in cancer. Semin Cancer Biol. 2006;16(6):420\u20136. https:\/\/doi.org\/10.1016\/j.semcancer.2006.10.009.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"3605_CR148","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1080\/14756366.2020.1712596","volume":"35","author":"M Krasavin","year":"2020","unstructured":"Krasavin M, Zalubovskis R, Grandane A, Domraceva I, Zhmurov P, Supuran C. Sulfocoumarins as dual inhibitors of human carbonic anhydrase isoforms IX\/XII and of human thioredoxin reductase. J Enzym Inhib Med Chem. 2020;35(1):506\u201310. https:\/\/doi.org\/10.1080\/14756366.2020.1712596.","journal-title":"J Enzym Inhib Med Chem"},{"issue":"14","key":"3605_CR149","doi-asserted-by":"publisher","first-page":"e70359","DOI":"10.1002\/cmdc.70359","volume":"21","author":"A Pustenko","year":"2026","unstructured":"Pustenko A, Bobrovs R, Saravanan V, Avan K, Carradori S, Sizovs A, et al. Sultams as Dual Inhibitors of Human Carbonic Anhydrase and Thioredoxin Reductase. ChemMedChem. 2026;21(14):e70359. https:\/\/doi.org\/10.1002\/cmdc.70359.","journal-title":"ChemMedChem"},{"issue":"13","key":"3605_CR150","doi-asserted-by":"publisher","first-page":"e70379","DOI":"10.1002\/cmdc.70379","volume":"21","author":"A Pustenko","year":"2026","unstructured":"Pustenko A, Bobrovs R, Freimane K, Sizovs A, Angeli A, Supuran CT, et al. Furagin Derivatives\u2014Nitrofuran-Based Hydrazones as Potential Dual Inhibitors of Thioredoxin Reductase and Carbonic Anhydrases. ChemMedChem. 2026;21(13):e70379. https:\/\/doi.org\/10.1002\/cmdc.70379.","journal-title":"ChemMedChem"},{"issue":"10","key":"3605_CR151","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/molecules24102005","volume":"24","author":"G Marconi","year":"2019","unstructured":"Marconi G, Gallorini M, Carradori S, Guglielmi P, Cataldi A, Zara S. The Up-Regulation of Oxidative Stress as a Potential Mechanism of Novel MAO-B Inhibitors for Glioblastoma Treatment. Molecules. 2019;24(10):16. https:\/\/doi.org\/10.3390\/molecules24102005.","journal-title":"Molecules"},{"key":"3605_CR152","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.bbrc.2022.03.096","volume":"606","author":"X Shui","year":"2022","unstructured":"Shui X, Ren X, Xu R, Xie Q, Hu Y, Qin J, et al. Monoamine oxidase A drives neuroendocrine differentiation in prostate cancer. Biochem Biophys Res Commun. 2022;606:135\u201341. https:\/\/doi.org\/10.1016\/j.bbrc.2022.03.096.","journal-title":"Biochem Biophys Res Commun"},{"issue":"22","key":"3605_CR153","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/molecules27227884","volume":"27","author":"M Agamennone","year":"2022","unstructured":"Agamennone M, Fantacuzzi M, Carradori S, Petzer A, Petzer J, Angeli A, et al. Coumarin-Based Dual Inhibitors of Human Carbonic Anhydrases and Monoamine Oxidases Featuring Amino Acyl and (Pseudo)-Dipeptidyl Appendages: In Vitro and Computational Studies. Molecules. 2022;27(22):24. https:\/\/doi.org\/10.3390\/molecules27227884.","journal-title":"Molecules"},{"issue":"1","key":"3605_CR154","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41467-021-21993-9","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wang W, Wu H, Zhou Y, Qin X, Wang Y, et al. The essential role of PRAK in tumor metastasis and its therapeutic potential. Nat Commun. 2021;12(1):14. https:\/\/doi.org\/10.1038\/s41467-021-21993-9.","journal-title":"Nat Commun"},{"key":"3605_CR155","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.bioorg.2026.110170","volume":"180","author":"M Fakhry","year":"2026","unstructured":"Fakhry M, Said M, Zeidan N, Ammara A, Bouajila J, Alkabbani M, et al. Rational design and synthesis of pyrazole-based sulfonamides as dual carbonic anhydrase and PRAK-targeting anticancer agents. Bioorg Chem. 2026;180:18. https:\/\/doi.org\/10.1016\/j.bioorg.2026.110170.","journal-title":"Bioorg Chem"},{"issue":"4","key":"3605_CR156","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1039\/d4md00837e","volume":"16","author":"S Bindra","year":"2025","unstructured":"Bindra S, Mostafa E, Abdelgawad M, Selim S, Kumar S, Mathew B. Synthetic strategies and medicinal chemistry perspectives of dual acting carbonic anhydrase modulators with monoamine oxidase and cholinesterase inhibitors. RSC Med Chem. 2025;16(4):1532\u201349. https:\/\/doi.org\/10.1039\/d4md00837e.","journal-title":"RSC Med Chem"},{"issue":"20","key":"3605_CR157","doi-asserted-by":"publisher","first-page":"20859","DOI":"10.1021\/acs.jmedchem.5c00287","volume":"68","author":"M Ishikawa","year":"2025","unstructured":"Ishikawa M, Tomoshige S, Sato S. Challenges of Aufheben to Promote Druglikeness: Chemical Modification Strategies to Improve Aqueous Solubility and Permeability. J Med Chem. 2025;68(20):20859\u2013902. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c00287.","journal-title":"J Med Chem"},{"issue":"5","key":"3605_CR158","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1124\/dmd.106.012781","volume":"35","author":"H Zhang","year":"2007","unstructured":"Zhang H, Zhang D, Li W, Yao M, D\u2019Arienzo C, Li Y, et al. Reduction of site-specific CYP3A-mediated metabolism for dual angiotensin and endothelin receptor antagonists in various in vitro systems and in cynomolgus monkeys. Drug Metab Dispos. 2007;35(5):795\u2013805. https:\/\/doi.org\/10.1124\/dmd.106.012781.","journal-title":"Drug Metab Dispos"},{"key":"3605_CR159","doi-asserted-by":"publisher","unstructured":"Fu C, Chen Q. The future of pharmaceuticals: Artificial intelligence in drug discovery and development. J Pharm Anal. 2025;101248. https:\/\/doi.org\/10.1016\/j.jpha.2025.101248.","DOI":"10.1016\/j.jpha.2025.101248"},{"issue":"3","key":"3605_CR160","doi-asserted-by":"publisher","first-page":"101144","DOI":"10.1016\/j.jpha.2024.101144","volume":"15","author":"B Wang","year":"2025","unstructured":"Wang B, Zhang T, Liu Q, Sutcharitchan C, Zhou Z, Zhang D, et al. Elucidating the role of artificial intelligence in drug development from the perspective of drug-target interactions. J Pharm Anal. 2025;15(3):101144. https:\/\/doi.org\/10.1016\/j.jpha.2024.101144.","journal-title":"J Pharm Anal"},{"issue":"6","key":"3605_CR161","doi-asserted-by":"publisher","first-page":"103992","DOI":"10.1016\/j.drudis.2024.103992","volume":"29","author":"A Gangwal","year":"2024","unstructured":"Gangwal A, Lavecchia A. Unleashing the power of generative AI in drug discovery. Drug Discov Today. 2024;29(6):103992. https:\/\/doi.org\/10.1016\/j.drudis.2024.103992.","journal-title":"Drug Discov Today"},{"key":"3605_CR162","doi-asserted-by":"publisher","unstructured":"Du M, Liu T, Wang W, Fan S, Tian M, Du Q, et al. PROTACs in Targeted Protein Degradation: Advances in Development and AI-Enhanced Drug Discovery. Eur J Med Chem Rep. 2026;100332. https:\/\/doi.org\/10.1016\/j.ejmcr.2026.100332.","DOI":"10.1016\/j.ejmcr.2026.100332"}],"container-title":["Medicinal Chemistry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03605-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00044-026-03605-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03605-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:04:06Z","timestamp":1788343446000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00044-026-03605-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":162,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3605"],"URL":"https:\/\/doi.org\/10.1007\/s00044-026-03605-7","relation":{},"ISSN":["1054-2523","1554-8120"],"issn-type":[{"value":"1054-2523","type":"print"},{"value":"1554-8120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"2 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}